DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Kenny-Caffey syndrome — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleKenny-Caffey syndrome maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for kenny-caffey syndrome is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
FAM111 trypsin like peptidase A (FAM111A) — FAM111A is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet apo structuredrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8S9K · 2.72 Å · ligand none (apo structure). Experimental structure, not a prediction.
What the evidence adds up to
Kenny-Caffey syndrome is a rare hereditary disorder characterised by short stature, hypoparathyroidism, and electrolyte disturbances. Two genetic forms exist: KCS1, caused by pathogenic variants in TBCE, and KCS2, caused by variants in FAM111A. A 2023 systematic review of 205 genetically confirmed cases found that the phenotypes of KCS1 and KCS2 overlap substantially. Postnatal growth retardation was reported in 52 of 52 KCS1 patients and 23 of 23 KCS2 patients. Low parathyroid hormone levels occurred in 121 of 121 KCS1 patients and 16 of 20 KCS2 patients. Electrolyte disturbances were present in 139 of 139 KCS1 patients and 24 of 27 KCS2 patients. Dental abnormalities, ocular abnormalities, and seizures or spasms were also common in both forms.
The same review identified features that help distinguish the two types. Intellectual disability was far more prevalent in KCS1 (74 of 80 patients) than in KCS2 (5 of 24 patients). Conversely, bone cortical thickening was reported in only 1 of 18 KCS1 patients but in 16 of 20 KCS2 patients, and medullary stenosis of the tubular bones occurred in 7 of 46 KCS1 patients versus 27 of 28 KCS2 patients. A 2020 description of KCS2 notes that it is autosomal dominant, with transient hypocalcemia, delayed closure of the anterior fontanel, eye anomalies including microphthalmia, proportionate short stature, and cortical thickening with medullary stenosis. An earlier 1989 report describes the syndrome generally as including growth retardation, slender long bones with medullary stenosis and thickened cortex, hypocalcemia possibly with tetany, hyperphosphatemia, ocular abnormalities, and normal intelligence.
The 2023 case series of ten KCS2 patients from seven families identified chronic kidney disease in 6 of 10 patients and intellectual disability in 3 of 10, findings not previously considered common in KCS2. The systematic review therefore established chronic kidney disease as a new feature of KCS2. No drug treatment for Kenny-Caffey syndrome is mentioned in any of these abstracts. What remains missing are prospective studies to clarify the natural history of chronic kidney disease in KCS2, standardised protocols for managing hypocalcemia and electrolyte disturbances across the lifespan, and any clinical trials of targeted or supportive therapies.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Clinical Pediatrics · 1989 · 18 citations
Kenny-Caffey Syndrome
AbstractKenny-Caffey Syndrome is a rare syndrome characterized by growth retardation, uniformly small slender long bones with medullary stenosis, thickened cortex of the long bones, hypocalcemia possibly with tetany at an early age, hyperphosphatemia, ocular abnormalities, and normal intelligence. We report a child with Kenny-Caffey Syndrome and idiopathic hypoparathyroidism and present a review of the literature summarizing the reported cases of this rare syndrome.
AbstractCaffey's disease is a self limited disorder of infantile age group. It is synonymous with 'infantile cortical hyperostosis' and 'Caffey's-Silver syndrome'.It is characterized by fever, irritability, bone pain and characteristic bony changes. It has no definite etiology. This report describes a 4 months old infant presenting with fever, irritability and soft tissue swellings. Investigations led to the diagnosis of Caffey's disease. Symptomatic treatment was given to good clinical response.
Veterinary Medicine and Science · 2023 · 1 citations · open access
Use of haemodiafiltration in the treatment of massive caffeine intoxication in a dog
AbstractThe objective of this case report is to describe the use of extracorporeal therapy, specifically hemodialfiltration, for the treatment of caffeine intoxication. A 12 year old Border Terrier consumed up to 1440 mg/kg of caffeine and rapidly developed clinical signs of tachycardia and tremors. Hemodiafiltration was instituted, using an M60 PrismaFlex cartridge using blood to prime the system due to patient size. Treatment with 11.25 L of therapy fluid (83% dialysate, 17% replacement fluid), or 1.8 L/kg, was provided over 6 h. Pre-treatment serum caffeine concentration of 233 µg/mL was decreased by 89% to 25 µg/nL by the end of treatment. Despite prompt institution of extracorporeal toxin removal therapy, ventricular ectopy developed necessitating sotolol treatment for the following week. Caffeine is efficiently removed via hemodialysis, as predicted by small size, small volume of distribution, and minimal protein binding. A CRRT platform can be used to provide adequate clearance.
AbstractAn autosomal dominant form of Kenny-Caffey Syndrome due to mutation(s) in the FAM111A gene, encoding protein FAM111A.T his condition is characterized by transient hypocalcemia, delayed closure of the anterior fontanel, eye anomalies, including microphthalmia, proportionate short stature, and cortical thickening and medullary stenosis of the tubular bones.
Abstract<strong>ABSTRACT</strong> <strong>Context - </strong>Kenny-Caffey syndrome (KCS) is a rare hereditary disorder characterized by short stature, hypoparathyroidism and electrolyte disturbances. KCS1 and KCS2 are caused by pathogenic variants in <em>TBCE</em> and <em>FAM111A</em>, respectively. Clinically the phenotypes are difficult to distinguish. <strong>Objective - </strong>The objective was to determine and expand the phenotypic spectrum of KCS1 and KCS2 in order to anticipate on complications that may arise in these disorders. <strong>Design - </strong>We clinically and genetically analyzed ten KCS2 patients from seven families. Because we found unusual phenotypes in our cohort, we performed a systematic review of genetically confirmed KCS cases using PubMed and Scopus. Evaluation by three researchers led to the inclusion of 26 papers for KCS1 and 16 for KCS2, totaling 205 patients. Data were extracted following the Cochrane guidelines and assessed by two independent researchers. <strong>Results - </strong>Several patients in our KCS2 cohort presented with intellectual disability (3/10) and chronic kidney disease (6/10), which are not considered common findings in KCS2. Systematic review of all reported KCS cases showed that the phenotypes of KCS1 and KCS2 overlap for postnatal growth retardation (KCS1: 52/52, KCS2: 23/23), low PTH levels (121/121, 16/20), electrolyte disturbances (139/139, 24/27), dental abnormalities (47/50, 15/16), ocular abnormalities (57/60, 22/23) and seizures/spasms (103/115, 13/16). Symptoms more prevalent in KCS1 included intellectual disability (74/80, 5/24), whereas in KCS2 bone cortical thickening (1/18, 16/20) and medullary stenosis (7/46, 27/28) were more common. <strong>Conclusions - </strong>Our case series established chronic kidney disease as a new feature of KCS2. In literature, we found substantial overlap in the phenotypic spectra of KCS1 and KCS2, but identified intellectual disability and the abnormal bone phenotype as the most distinguishing features.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
